Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension

Abstract Background This was a phase 3, randomized, double-blind, placebo-controlled study. Methods Adult Korean patients with essential hypertension and a baseline mean sitting clinic systolic blood pressure (scSBP) ≥150 and ≤180 mmHg were randomized to 6-week treatment with placebo (n = 65), azils...

Full description

Bibliographic Details

Published in:	Clinical Hypertension
Main Authors:	Attila Juhasz, Jingtao Wu, Michie Hisada, Tomoka Tsukada, Myung Ho Jeong
Format:	Article
Language:	English
Published:	XMLink 2018-02-01
Subjects:	Hypertension Azilsartan medoxomil Angiotensin II receptor antagonist Blood pressure Korea
Online Access:	http://link.springer.com/article/10.1186/s40885-018-0086-4